Cystatin C and cysteine proteinases during the development and therapy of Lewis lung adenocarcinoma in mice.
We measured plasma cystatin C concentration and activity of cathepsins B and L in tumor tissue as possible markers for the efficiency of antitumor therapy and prognostic criteria for Lewis lung adenocarcinoma in mice. Plasma cystatin C concentration markedly decreased in mice with tumors. During successive therapy the increase in plasma cystatin C concentration correlated with the degree of inhibition of tumor growth. Activities of cathepsins B and L in the liver increased in animals with tumors. In mice receiving successive antitumor therapy activities of cathepsins B and L increased in tumor tissue, but decreased in the liver (compared to untreated animals).
Usova
T A
TA
Institute of Physiology, Siberian Division of the Russian Academy of Medical Sciences, Novosibirsk.
Poteryaeva
O N
ON
Zhanayeva
S Ya
SY
Yarygina
E S
ES
Korolenko
T A
TA
D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D018827:Carcinoma, Lewis Lung / Q000097:blood* / Q000188:drug therapy; D002401:Cathepsin B / Q000097:blood*; D056668:Cathepsin L; D002403:Cathepsins / Q000097:blood*; D003520:Cyclophosphamide / Q000627:therapeutic use; D055316:Cystatin C; D015891:Cystatins / Q000097:blood*; D003546:Cysteine Endopeptidases; D008297:Male; D051379:Mice; D011379:Prognosis
D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; C525031:Cst3 protein, mouse; D055316:Cystatin C; D015891:Cystatins; D003520:Cyclophosphamide; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D002401:Cathepsin B; D056668:Cathepsin L; C534278:Ctsl protein, mouse